Literature DB >> 16873793

Deficiencies of cardiovascular risk prediction models for type 1 diabetes.

Janice C Zgibor1, Gretchen A Piatt, Kristine Ruppert, Trevor J Orchard, Mark S Roberts.   

Abstract

OBJECTIVE: Cardiovascular risk prediction models are available for the general population (Framingham) and for type 2 diabetes (U.K. Prospective Diabetes Study [UKPDS] Risk Engine) but may not be appropriate in type 1 diabetes, as risk factors including younger age at diabetes onset and presence of diabetes complications are not considered. Therefore, our objective was to examine the accuracy of Framingham and UKPDS models for predicting coronary heart disease (CHD) in a type 1 diabetic cohort. RESEARCH DESIGN AND METHODS: Ten-year follow-up data from the Pittsburgh Epidemiology of Diabetes Complications (EDC) study, a prospective cohort study of 658 subjects with childhood-onset type 1 diabetes diagnosed between 1950 and 1980 first seen in 1986-1988, were analyzed. EDC study data were used to calculate the 10-year probability of CHD (fatal CHD, nonfatal myocardial infarction, or Q-waves) applying to the Framingham and UKPDS equations.
RESULTS: Mean age at CHD onset was 39 years. When fatal/nonfatal myocardial infarction and CHD death were modeled, both the UKPDS and Framingham models showed significant lack of calibration (P < 0.0001) but moderate discrimination (0.76 UKPDS, 0.77 Framingham men, and 0.88 Framingham women). Both the UKPDS and Framingham models underestimated probability of events in highest risk deciles.
CONCLUSIONS: Currently available CHD models poorly predict events in type 1 diabetes. Future research should focus on determining the risk factors accounting for the lack of fit and developing prediction models specific to this high-risk group.

Entities:  

Mesh:

Year:  2006        PMID: 16873793     DOI: 10.2337/dc06-0290

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  22 in total

1.  Development of a coronary heart disease risk prediction model for type 1 diabetes: the Pittsburgh CHD in Type 1 Diabetes Risk Model.

Authors:  Janice C Zgibor; Kristine Ruppert; Trevor J Orchard; Sabita S Soedamah-Muthu; John Fuller; Nish Chaturvedi; Mark S Roberts
Journal:  Diabetes Res Clin Pract       Date:  2010-03-16       Impact factor: 5.602

2.  Features of hepatic and skeletal muscle insulin resistance unique to type 1 diabetes.

Authors:  Bryan C Bergman; David Howard; Irene E Schauer; David M Maahs; Janet K Snell-Bergeon; Robert H Eckel; Leigh Perreault; Marian Rewers
Journal:  J Clin Endocrinol Metab       Date:  2012-02-22       Impact factor: 5.958

3.  Spontaneously diabetic Ins2(+/Akita):apoE-deficient mice exhibit exaggerated hypercholesterolemia and atherosclerosis.

Authors:  John Y Jun; Zhexi Ma; Lakshman Segar
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-03-29       Impact factor: 4.310

4.  The role of coronary artery calcification testing in incident coronary artery disease risk prediction in type 1 diabetes.

Authors:  Jingchuan Guo; Sebhat A Erqou; Rachel G Miller; Daniel Edmundowicz; Trevor J Orchard; Tina Costacou
Journal:  Diabetologia       Date:  2018-11-14       Impact factor: 10.122

Review 5.  Heart disease and rheumatoid arthritis: understanding the risks.

Authors:  S E Gabriel
Journal:  Ann Rheum Dis       Date:  2010-01       Impact factor: 19.103

Review 6.  When are type 1 diabetic patients at risk for cardiovascular disease?

Authors:  Trevor J Orchard; Tina Costacou
Journal:  Curr Diab Rep       Date:  2010-02       Impact factor: 4.810

7.  Data-driven metabolic subtypes predict future adverse events in individuals with type 1 diabetes.

Authors:  Raija Lithovius; Iiro Toppila; Valma Harjutsalo; Carol Forsblom; Per-Henrik Groop; Ville-Petteri Mäkinen
Journal:  Diabetologia       Date:  2017-04-24       Impact factor: 10.122

Review 8.  Vascular calcification in diabetes: mechanisms and implications.

Authors:  Janet K Snell-Bergeon; Matthew J Budoff; John E Hokanson
Journal:  Curr Diab Rep       Date:  2013-06       Impact factor: 4.810

9.  The cost-effectiveness of continuous glucose monitoring in type 1 diabetes.

Authors:  Elbert S Huang; Michael O'Grady; Anirban Basu; Aaron Winn; Priya John; Joyce Lee; David Meltzer; Craig Kollman; Lori Laffel; William Tamborlane; Stuart Weinzimer; Tim Wysocki
Journal:  Diabetes Care       Date:  2010-03-23       Impact factor: 17.152

Review 10.  Integrating Biomarkers and Imaging for Cardiovascular Disease Risk Assessment in Diabetes.

Authors:  David M Tehrani; Nathan D Wong
Journal:  Curr Cardiol Rep       Date:  2016-11       Impact factor: 2.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.